{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"058-295-270-366-965","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"058-295-270-366-965"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11811,"type":"PATENT","title":"TU Dresden Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4969,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8441,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: tech* uni* dresden. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4718
Search Applicants and Owners separately: tech* uni* dresden. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4718
(a) ICA512, ICA512-TMF or ICA512-CCF, each devoid of the C-terminus or PHOGRIN devoid of the C-terminus or of a mimetic of the C-terminus of ICA512, ICA512-TMF, ICA512-CCF or PHOGRIN;
(b) a compound promoting the presence or activity of a protease that cleaves the C-terminus of ICA512, ICA512-TMF or ICA512-CCF or PHOGRIN;
(c) a compound promoting the presence or activity of a serine/threonine kinase which phosphorylates β2-syntrophin on serine residue 95;
(d) a compound interfering with the presence or activity of a serine/threonine phosphatase which dephosphorylates β2-syntrophin on serine residue 95;
(e) a compound promoting the presence or activity of a serine/threonine phosphatase which dephosphorylates β2-syntrophin on serine residue 110; or
(f) a compound interfering with the presence or activity of a serine/threonine kinase which phosphorylates β2-syntrophin on serine residue 110."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["Use of
(a) ICA512, ICA512-TMF or ICA512-CCF, each devoid of the C-terminus or PHOGRIN devoid of the C-terminus or of a mimetic of the C-terminus of ICA512, ICA512-TMF, ICA512-CCF or PHOGRIN;
(b) a compound promoting the presence or activity of a protease that cleaves the C-terminus of ICA512, ICA512-TMF, ICA512-CCF or PHOGRIN;
(c) a compound promoting the presence or activity of a serine/threonine kinase which phosphorylates β2-syntrophin on serine residue 95;
(d) a compound interfering with the presence or activity of a. serine/threonine phosphatase which dephosphorylates β2-syntrophin on serine residue 95;
(e) a compound promoting the presence or activity of a serine/threonine phosphatase which dephosphorylates β2-syntrophin on serine residue 110; or
(f) a compound interfering with the presence or activity of a serine/threonine kinase which phosphorylates β2-syntrophin on serine residue 110for the preparation of a pharmaceutical composition for the treatment of diabetes."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1 or the use of claim 2 wherein said mimetic is a peptidomimetic."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1 or the use of claim 2 wherein the compound promoting the presence or activity of said protease that cleaves the C-terminus of ICA512, ICA512-TMF, ICA512-CCF or PHOGRIN is an expression vector containing the coding region of said protease in expressible form."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1 or the use of claim 2 wherein the compound promoting the presence or activity of said serine/threonine kinase is an expression vector containing the coding region of said kinase in expressible form."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1 or the use of claim 2 wherein the compound promoting the presence or activity of said serine/threonine phosphatase is an expression vector containing the coding region of said phosphatase in expressible form."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["A method of enhancing insulin secretion from pancreatic β-cells comprising promoting in said β-cells the presence or activity of
(a) (aa) ICA512, ICA512-TMF, ICA512-CCF or PHOGRIN; or(ab) ICA512, ICA512-TMF or ICA512-CCF, each devoid of the C-terminus or PHOGRIN devoid of the C-terminus;
(b) a compound promoting the presence or activity of a protease that cleaves the C-terminus of ICA512, ICA512-TMF, ICA512-CCF or PHOGRIN;
(c) a compound promoting the presence or activity of serine/threonine kinase which phosphorylates β2-syntrophin on serine residue 95;
(d) a compound interfering with the presence or activity of serine/threonine phosphatase which dephosphorylates β2-syntrophin on serine residue 95;
(e) a compound promoting the presence or activity of a phosphatase which dephosphorylates β2-syntrophin on serine residue 110; or
(f) a compound interfering with the presence or activity of a serine/threonine kinase which phosphorylates ß2-syntrophin on serine residue 110."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7 wherein the promotion comprises the stable or transient expression from an exogenously introduced vector of said
(a) (aa) ICA512, ICA512-TMF, ICA512-CCF or PHOGRIN; or(ab) ICA512, ICA512-TMF or ICA512-CCF, each devoid of the C-terminus or PHOGRIN devoid of the C-terminus;
(b) compound promoting the presence or activity of a protease that cleaves the C-terminus of ICA512, ICA512-TMF, ICA512-CCF or PHOGRIN;
(c) compound promoting the presence or activity of a serine/threonine kinase which phosphorylates β2-syntrophin on serine residue 95;
(d) compound interfering with the expression or activity of a serine/threonine phosphatase which dephosphorylates ß2-syntrophin on serine residue 95;
(e) compound promoting the presence or activity of a serine/threonine phosphatase which dephosphorylates β2-syntrophin on serine residue 110; or
(f) compound interfering with the expression or activity of a serine/threonine kinase which phosphorylates β2-syntrophin on serine residue 110."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of any one of claims 1 to 6, the use of any one of claims 2 to 6 or the method of claim 7 wherein the promotion comprises reducing degradation or enhancing stability in said β-cells of said
(a) (aa) ICA512, ICA512-TMF, ICA512-CCF or PHOGRIN; or(ab) ICA512, ICA512-TMF or ICA512-CCF, each devoid of the C-terminus or PHOGRIN devoid of the C-terminus;
(b) compound promoting the presence or activity of a protease that cleaves the C-terminus of ICA512, ICA512-TMF, ICA512-CCF or PHOGRIN;
(c) compound promoting the presence or activity of a serine/threonine kinase which phosphorylates β2-syntrophin on serine residue 95;
(d) compound interfering with the presence or activity of a serine/threonine phosphatase which dephosphorylates β2-syntrophin on serine residue 95;
(e) compound promoting the presence or activity of a serine/threonine phosphatase which dephosphorylates β2-syntrophin on serine residue 110; or said
(f) compound interfering with the presence or activity of a serine/threonine kinase which phosphorylates β2-syntrophin on serine residue 110."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of any one of claims 1 to 6 and 9, the use of any one of claims 2 to 6 and 9 or the method of any one of claims 7 to 9 wherein the compound interfering with the presence or activity of said phosphatase or of said kinase is an siRNA, an shRNA, a ribozyme, a peptide aptamer, a nucleic acid based aptamer, a small molecule or an antibody."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A method of identifying a compound useful in the enhancement of insulin secretion from pancreatic β-cells or useful as a lead compound for developing a compound useful in the enhancement of insulin secretion from pancreatic β-cells comprising contacting a compound or a plurality of compounds suspected to be useful in the enhancement of insulin secretion from pancreatic β-cells or useful as a lead compound for developing a compound useful in the enhancement of insulin secretion from pancreatic β-cells with a mixture of (a) ICA512, ICA512-TMF, ICA512-CCF and/or PHOGRIN; and (b) β2-syntrophin and/or the PDZ domain of β2-syntrophin in vitro under conditions that would allow binding of ICA512, ICA512-TMF, ICA512-CCF and/or PHOGRIN to β2-syntrophin and/or the PDZ domain of β2-syntrophin in the absence of the compound or the plurality of compounds and assessing binding of ICA512, ICA512-TMF, ICA512-CCF and/or PHOGRIN to β2-syntrophin and/or the PDZ domain of β2-syntrophin wherein an interference of binding of ICA512, ICA512-TMF, ICA512-CCF and/or PHOGRIN to β2-syntrophin and/or the PDZ domain of β2-syntrophin in the presence of said compound or said plurality of compounds is indicative of said compound or at least one member of said plurality of compounds being useful in the enhancement of insulin secretion from pancreatic β-cells or useful as a lead compound for developing a compound useful in the enhancement of insulin secretion from pancreatic β-cells."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A method of identifying a compound useful in the treatment of diabetes or useful as a lead compound for developing a compound useful in the treatment of diabetes comprising in silico assessing a crystal of ICA512 or PHOGRIN or a crystal of a fragment of ICA512 or PHOGRIN comprising the PTP domain for a molecular structure fitting into the binding pocket of the PTP domain."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A method of identifying a compound useful for enhancing insulin secretion from pancreatic β-cells or useful as a lead compound for developing a compound useful enhancing insulin secretion from pancreatic β-cells comprising in silico assessing a crystal of ICA512 or PHOGRIN or a crystal of a fragment of ICA512 or PHOGRIN comprising the PTP domain for a molecular structure fitting into the binding pocket of the PTP domain."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["A method of identifying a compound useful for enhancing insulin secretion from pancreatic β-cells or useful as a lead compound for developing a compound useful enhancing insulin secretion from pancreatic β-cells comprising in silico assessing a crystal of β2-syntrophin or a crystal of a fragment of β2-syntrophin comprising the PDZ domain for a molecular structure fitting into the binding pocket of the PDZ domain."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 12 to 14 further comprising in silico or in vitro assessing whether (a) the compound fitting into the binding pocket of the PTP domain interferes with binding of said domain or of ICA512, ICA-TMF, ICA-CCF or PHOGRIN with β2-syntrophin; or (b) the compound fitting into the binding pocket of the PDZ domain interferes with binding of said domain or of β2-syntrophin with ICA512, ICA-TMF, ICA-CCF or PHOGRIN."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15 further comprising chemically synthesizing (a) the compound fitting into the binding pocket of the PTP domain and in silico or in vitro interfering with the binding of the PTP domain or of ICA512, ICA-TMF, ICA-CCF or PHOGRIN to β2-syntrophin; or (b) the compound fitting into the binding pocket of the PDZ domain and in silico or in vitro interfering with the binding of the PDZ domain or β2-syntrophin with ICA512, ICA-TMF, ICA-CCF or PHOGRIN."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of any one of claims 1 to 6, the use of any one of claims 1 to 6 or the method of any one of claims 7 to 16 wherein said kinase is CDK5."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition, use or method of any of the preceding claims wherein said compound is a small molecule, a peptide, and antibody, a peptide aptamer, a nucleic acid aptamer, a glucose metabolite, an anticalin, an siRNA, an shRNA, a ribozyme, an antisense nucleic acid molecule or a mimetic, preferably a peptidomimetic.."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["Use of a glucose metabolite or a derivative thereof for the preparation of a pharmaceutical composition for the treatment of diabetes."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The use of claim 19 wherein said glucose metabolite is glyceraldehyde-3-phosphate."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition, use or method of any of the preceding claims wherein said diabetes is type-2 diabetes."],"number":21,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}